The Microscopy and Cell Analysis Core is fully equipped and expertly staffed to perform specimen preparation, light and electron microscopy, photography, digital imaging, and multi-parameter Flow and Cell Sorting services to Mayo Clinic Cancer Center investigators from both clinical and basic science laboratories. The facility also performs X-ray probe microanalysis, immuno-gold labeling, 3-D EM reconstruction from serial-sectioned specimens, and high-resolution reconstruction using image averaging of negative stained and cryo-tomography imaged specimens. Instrumentation and expertise are also supported in the core for high-end optical, two-photon, super-resolution, laser confocal, TIRF, ratio imaging, and other optical methods, as well as Flow Cytometry and Live Cell Sorting technologies and analysis. Additionally, the core staff (23 FTEs) and the core director are available for the development and/or implementation of new microscopy techniques and for testing and evaluation of instrumentation that would be of value to individual Mayo Cancer Center investigators and the greater research community. During the last budget year, the Microscopy and Cell Analysis Shared Resource has been widely utilized by each of the Mayo Cancer Center Programs. During the past 12 months, the facility served over 100 Mayo Cancer Center investigators processing 1000-plus specimens for electron microscopy, and logging 5,000 hours of Optical Microscopy and over 5000 hours of Flow Analysis and Cell Sorting. Because of the large expense for purchase and maintenance of high-end optical and electron microscopes, and the expertise required for their productive use, most investigators and their research laboratories find the Microscopy and Cell Analysis Core services to be the most economical, practical, and up-to-date means to achieve their sophisticated microscopy and cell sorting and analysis research needs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393

Showing the most recent 10 out of 1086 publications